FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563560423> ?p ?o ?g. }

• W2563560423 abstract "Abstract OBJECTIVES: With a greater focus on costs in today’s health care markets, it is important to evaluate overall costs and quality of care associated with new therapies in cost-effectiveness analyses. Adverse events (AEs) associated with cancer therapies often result in substantial economic costs and negative impacts on patient quality of life. AEs may also affect adherence to therapy and result in suboptimal treatment outcomes. Important AEs of dasatinib in chronic myelogenous leukemia (CML) patients who are resistant to imatinib include neutropenia, thrombocytopenia, anemia, gastrointestinal hemorrhage, central nervous system hemorrhage, and fluid retention leading to effusions and heart dysfunction. This study evaluated the total cost of treatment with dasatinib in patients with chronic, accelerated, and myeloid blast phase CML, taking into account both drug and AE-associated costs. METHODS: A literature-based economic model was developed to examine the short-term potential impact of AEs in patients with CML treated with dasatinib. The incidence rates of Grade 3/4 AEs were obtained from the SPRYCEL™ (dasatinib) package insert. The AEs were assumed to occur within the first 6 months of treatment. The costs associated with the AEs were obtained from published medical literature and the 2003 Healthcare Cost and Utilization Project database of mean hospital charges by principal diagnosis, converting to costs using a Medicare cost-to-charge ratio of 0.55. Dasatinib dosing assumptions were based on the FDA briefing documents of the SPRYCEL™ filing submission presented at the June 2, 2006 Oncology Drug Advisory Committee meeting. The initial dose for dasatinib was 70 mg twice daily based on the package insert. Patients were assumed to remain on treatment for 6 months. However, dose interruption of 7–14 days during the first 3 months of treatment and dose reduction to 50 mg twice daily in the second 3 months of treatment were assumed in 46–55% and 9–10% of patients, respectively. Drug costs were based on wholesale acquisition cost. Univariate and multivariate sensitivity analyses were conducted. All costs were adjusted to 2006 U.S. dollars using the medical care component of the consumer price index. RESULTS: In the base case analysis, the expected 6-month per-patient cost of treatment for dasatinib was $31,528 for chronic phase, $44,340 for accelerated phase, and $48,666 for myeloid blast phase. Six-month drug cost alone was $22,284 per patient in each phase. Grade 3/4 AEs accounted for approximately 29%, 50%, and 54% of the total cost of care for chronic, accelerated, and myeloid blast phases, respectively. Sensitivity analysis showed that the 6-month cost of Grade 3/4 AEs may range from $5,235–$10,696 for chronic, $16,109–$23,723 for accelerated, and $12,971–$27,551 for myeloid blast phases. Primary cost drivers were the hematologic AEs. CONCLUSIONS: This study provides an estimate for the total cost of treatment with dasatinib that considers treatment costs for severe AEs associated with therapy. These results highlight the importance of including treatment-related AEs in addition to drug costs when assessing the economic value of treatment options for CML. Future studies should expand the time horizon of the analysis and include recurring AEs to more comprehensively evaluate the overall economic impact of AEs with dasatinib." @default.
• W2563560423 created "2017-01-06" @default.
• W2563560423 creator A5024580938 @default.
• W2563560423 creator A5035272901 @default.
• W2563560423 creator A5037632435 @default.
• W2563560423 creator A5046622222 @default.
• W2563560423 creator A5087184017 @default.
• W2563560423 date "2006-11-16" @default.
• W2563560423 modified "2023-10-14" @default.
• W2563560423 title "Economic Impact of Adverse Events in Chronic Myelogenous Leukemia: A Cost of Treatment Analysis of Dasatinib." @default.
• W2563560423 doi "https://doi.org/10.1182/blood.v108.11.3309.3309" @default.
• W2563560423 hasPublicationYear "2006" @default.
• W2563560423 type Work @default.
• W2563560423 sameAs 2563560423 @default.
• W2563560423 citedByCount "1" @default.
• W2563560423 crossrefType "journal-article" @default.
• W2563560423 hasAuthorship W2563560423A5024580938 @default.
• W2563560423 hasAuthorship W2563560423A5035272901 @default.
• W2563560423 hasAuthorship W2563560423A5037632435 @default.
• W2563560423 hasAuthorship W2563560423A5046622222 @default.
• W2563560423 hasAuthorship W2563560423A5087184017 @default.
• W2563560423 hasConcept C112930515 @default.
• W2563560423 hasConcept C126322002 @default.
• W2563560423 hasConcept C143998085 @default.
• W2563560423 hasConcept C177713679 @default.
• W2563560423 hasConcept C194828623 @default.
• W2563560423 hasConcept C197934379 @default.
• W2563560423 hasConcept C2776960273 @default.
• W2563560423 hasConcept C2777583451 @default.
• W2563560423 hasConcept C2778461978 @default.
• W2563560423 hasConcept C2778729363 @default.
• W2563560423 hasConcept C2779536868 @default.
• W2563560423 hasConcept C3019080777 @default.
• W2563560423 hasConcept C71924100 @default.
• W2563560423 hasConceptScore W2563560423C112930515 @default.
• W2563560423 hasConceptScore W2563560423C126322002 @default.
• W2563560423 hasConceptScore W2563560423C143998085 @default.
• W2563560423 hasConceptScore W2563560423C177713679 @default.
• W2563560423 hasConceptScore W2563560423C194828623 @default.
• W2563560423 hasConceptScore W2563560423C197934379 @default.
• W2563560423 hasConceptScore W2563560423C2776960273 @default.
• W2563560423 hasConceptScore W2563560423C2777583451 @default.
• W2563560423 hasConceptScore W2563560423C2778461978 @default.
• W2563560423 hasConceptScore W2563560423C2778729363 @default.
• W2563560423 hasConceptScore W2563560423C2779536868 @default.
• W2563560423 hasConceptScore W2563560423C3019080777 @default.
• W2563560423 hasConceptScore W2563560423C71924100 @default.
• W2563560423 hasLocation W25635604231 @default.
• W2563560423 hasOpenAccess W2563560423 @default.
• W2563560423 hasPrimaryLocation W25635604231 @default.
• W2563560423 hasRelatedWork W1603075288 @default.
• W2563560423 hasRelatedWork W1984313504 @default.
• W2563560423 hasRelatedWork W2023117511 @default.
• W2563560423 hasRelatedWork W2065400699 @default.
• W2563560423 hasRelatedWork W2411429473 @default.
• W2563560423 hasRelatedWork W2554271828 @default.
• W2563560423 hasRelatedWork W2563560423 @default.
• W2563560423 hasRelatedWork W2573996312 @default.
• W2563560423 hasRelatedWork W2809163127 @default.
• W2563560423 hasRelatedWork W3036821862 @default.
• W2563560423 isParatext "false" @default.
• W2563560423 isRetracted "false" @default.
• W2563560423 magId "2563560423" @default.
• W2563560423 workType "article" @default.